Status | Study |
Recruiting |
Study Name: A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium Condition: Arthritis, Psoriatic Date: 2017-03-24 Interventions: Drug: apremilast Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium |
Recruiting |
Study Name: Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions Condition: Arthritis, Psoriatic Date: 2017-03-17 |
Recruiting |
Study Name: Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Condition: Plaque Psoriasis Date: 2017-02-22 Interventions: Drug: Secukinumab 150 mg s.c. |
Recruiting |
Study Name: Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis Condition: Psoriatic Arthritis Date: 2017-02-13 Interventions: Drug: Fecal microbiota transplantation (FMT) |
Recruiting |
Study Name: The Norwegian Drug Monitoring Study Condition: Rheumatoid Arthritis Spondyloarthritis Ankylosing Spondyli Date: 2017-02-10 Interventions: Other: Therapeutic drug monitoring |
Not yet recruiting |
Study Name: Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective. Condition: Psoriatic Arthritis Date: 2017-01-04 |
Recruiting |
Study Name: Tracking Biologics Along the Silk Road Condition: Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative Date: 2016-12-28 |
Not yet recruiting |
Study Name: Low Dose Naltrexone for Chronic Pain From Arthritis Condition: Osteoarthritis Arthritis, Rheumatoid Date: 2016-12-22 Interventions: Drug: Naltrexone One 4.5 mg ca |
Completed |
Study Name: Interval Training Study in Psoriatic Arthritis Condition: Psoriatic Arthritis Date: 2016-12-14 Interventions: Behavioral: interval training 4x4 high intensity interval training |
Recruiting |
Study Name: A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5 Condition: Psoriatic Arthritis Date: 2016-12-06 Interventions: Biological: risankizumab Risankizumab administered by subcutaneous injection. |